Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Franchi

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
Thrombosis and Haemostasis|January 4, 2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic DiseaseMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
JACC. Basic to Translational Science|August 22, 2024
Clopidogrel-Mediated P2Y<sub>12</sub> Inhibition According to Renal Function in Patients With Diabetes Mellitus and CADLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
Pharmacogenomics|March 28, 2017
Institutional profile: University of Florida Health Personalized Medicine ProgramLarisa H Cavallari, Kristin W Weitzel, Amanda R Elsey, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 18, 2020
Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selectionAmber L Beitelshees, James M Stevenson, Nihal El Rouby, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 5, 2020
Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selectionAmber L Beitelshees, James M Stevenson, Nihal El Rouby, et al.
Clinical Pharmacology and Therapeutics|August 28, 2025
Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel-Treated ParticipantsLuis Ortega-Paz, Cameron D Thomas, Claudio Laudani, et al.
Nature Reviews. Cardiology|July 6, 2018
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke preventionDavide Capodanno, Roxana Mehran, Marco Valgimigli, et al.
Journal of the American Heart Association|July 4, 2025
<i>CYP2C19</i> Phenotype, P2Y<sub>12</sub> Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel TherapyRajiv C Patel, Cameron D Thomas, Joseph S Rossi, et al.
JACC. Basic to Translational Science|January 31, 2020
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 StudyFrancesco Franchi, Fabiana Rollini, Victor Kairouz, et al.
Clinical and Translational Science|July 10, 2026
Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCICaroline W Grant, Brenden S Ingraham, Ryan J Lennon, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
Thrombosis and Haemostasis|January 4, 2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic DiseaseMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
JACC. Basic to Translational Science|August 22, 2024
Clopidogrel-Mediated P2Y<sub>12</sub> Inhibition According to Renal Function in Patients With Diabetes Mellitus and CADLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
Pharmacogenomics|March 28, 2017
Institutional profile: University of Florida Health Personalized Medicine ProgramLarisa H Cavallari, Kristin W Weitzel, Amanda R Elsey, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 18, 2020
Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selectionAmber L Beitelshees, James M Stevenson, Nihal El Rouby, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 5, 2020
Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selectionAmber L Beitelshees, James M Stevenson, Nihal El Rouby, et al.
Clinical Pharmacology and Therapeutics|August 28, 2025
Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel-Treated ParticipantsLuis Ortega-Paz, Cameron D Thomas, Claudio Laudani, et al.
Nature Reviews. Cardiology|July 6, 2018
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke preventionDavide Capodanno, Roxana Mehran, Marco Valgimigli, et al.
Journal of the American Heart Association|July 4, 2025
<i>CYP2C19</i> Phenotype, P2Y<sub>12</sub> Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel TherapyRajiv C Patel, Cameron D Thomas, Joseph S Rossi, et al.
JACC. Basic to Translational Science|January 31, 2020
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 StudyFrancesco Franchi, Fabiana Rollini, Victor Kairouz, et al.
Clinical and Translational Science|July 10, 2026
Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCICaroline W Grant, Brenden S Ingraham, Ryan J Lennon, et al.
Pageof 15